IPO TRACKER

A real-time look at every biotech IPO filed and the amount raised in all the world's indexes. Compiled by editor Max Gelman.

COMPANIES
RAISED
Traditional IPOs

4

621T

SPACs

0

0

TOTAL

4

621T

IPO Tracker Logo
Explore: 20212022
Q1
Struc­ture Ther­a­peu­tics
Min­eralys Ther­a­peu­tics
Q2
Ace­lyrin
Az­i­tra

FILED

Az­i­tra

Type & Stage
IPO: Filed
CEO
Francisco Salva
ticker
AZTR
exchange
NASDAQ
Filed Date
5 June
Est Raise
$8M

snapshot ▲

Farm­ing­ton, CT-based Az­i­tra raised close to $3 mil­lion in a Se­ries A de­signed to fu­el its re­search on mi­cro­bio­me ther­a­pies for the skin and now it wants to go pub­lic. The biotech filed for a place on the Nas­daq with plans to raise $8 mil­lion by of­fer­ing 1.5 mil­lion shares at a price range of $4.50 to $5.50 un­der the tick­er sym­bol $AZTR. Seed­ed by Pe­ter Thiel’s Break­out Labs, the com­pa­ny iden­ti­fied a strain of bac­te­ria that can be used in lo­tions to treat con­di­tions like eczema and staph in­fec­tions. The biotech’s lead pro­gram is ATR-12, with a Phase Ib to start in the first half of 2023 for Nether­ton syn­drome, a rare au­to­so­mal dis­ease caused by mu­ta­tions in the SPINK5 gene. The com­pa­ny says there are about 20,000 pa­tients world­wide with a po­ten­tial $250 mil­lion peak sales op­por­tu­ni­ty. Ear­li­er in the pipeline are ATR-04 for EGFR in­hibitor-as­so­ci­at­ed rash with an es­ti­mat­ed start date for its Phase Ib tri­al in the first half of 2024 and ATR-01 for ichthyosis vul­garis with an ex­pect­ed IND fil­ing date in late 2024.

coverage

PRICED

Ace­lyrin

Type & Stage
IPO: Priced
CEO
Shao-Lee Lin
ticker
SLRN
exchange
NASDAQ
IPO Date
4 May
Total Raised
$621T
Priced at
$18
Current Price
$9.34

snapshot ▲

Im­munol­o­gy bio­phar­ma Ace­lyrin raised $621 mil­lion at the clos­ing of its en­trance in­to the stock mar­ket with an up­sized ini­tial pub­lic of­fer­ing of 34.5 mil­lion shares of com­mon stock. At the time of a $250 mil­lion Se­ries B in 2021, Ace­lyrin CEO Shao-Lee Lin, who pre­vi­ous­ly led R&D at Hori­zon Ther­a­peu­tics, told End­points News that her com­pa­ny would pon­der an IPO “with­in the con­text of 2022.” They raised an­oth­er $300 mil­lion last fall. The com­pa­ny is in­ves­ti­gat­ing izok­ibep, an IL-17a in­hibitor, in mul­ti­ple Phase IIb/III stud­ies for mod­er­ate-to-se­vere hidradeni­tis sup­pu­ra­ti­va (HS), uveitis and pso­ri­at­ic arthri­tis with ex­pec­ta­tions for a da­ta drop as soon as the sec­ond half of 2023. Ace­lyrin paid Af­fi­body $25 mil­lion up­front in 2021 and will dole out up to $280 mil­lion more in reg­u­la­to­ry and sales mile­stones and roy­al­ties for the drug. Ace­lyrin has a Phase I thy­roid eye dis­ease can­di­date, an an­ti-IGF-1R dubbed lonigutam­ab. A Phase I/II tri­al in pa­tients is on­go­ing. Ace­lyrin al­so has SLRN-517, a ful­ly hu­man mon­o­clon­al an­ti­body tar­get­ing c-KIT, in a Phase I/II tri­al in both healthy vol­un­teers and chron­ic ur­ticaria pa­tients. That study is ac­tive­ly en­rolling.

coverage

Min­eralys Ther­a­peu­tics

Type & Stage
IPO: Priced
CEO
Jon Congleton
ticker
MLYS
exchange
NASDAQ
IPO Date
9 February
Total Raised
$220.8M
Priced at
$16
Current Price
$10.1

snapshot ▲

Drug de­vel­op­er Min­eralys Ther­a­peu­tics closed its IPO of 13.8 mil­lion shares of com­mon stock in Feb­ru­ary, col­lect­ing ag­gre­gate gross pro­ceeds of $220.8 mil­lion. The Penn­syl­va­nia-based com­pa­ny plans to use the mon­ey on de­vel­op­ment of its hy­per­ten­sion drug lorun­dro­stat, an al­dos­terone syn­thase in­hibitor. Min­eralys an­nounced in Ju­ly an ex­pand­ed, ex­plorato­ry two-part Phase II tri­al test­ing out lorun­dro­stat as a po­ten­tial treat­ment for stage 2 to 4 chron­ic kid­ney dis­ease. The com­pa­ny plans to start en­rolling pa­tients in the sec­ond half of 2023 while topline da­ta is ex­pect­ed be­tween the end of 2024 and the be­gin­ning of 2025. The biotech li­censed lorun­dro­stat from Japan’s Mit­subishi Tan­abe. Min­eralys first hit the scene in 2021 with $40 mil­lion in Se­ries A funds with its fo­cus on al­dos­terone, a hor­mone linked to in­creased blood pres­sure and a con­trib­u­tor to the de­vel­op­ment and pro­gres­sion of chron­ic kid­ney dis­ease.

coverage

Struc­ture Ther­a­peu­tics

Type & Stage
IPO: Priced
CEO
Raymond Stevens
ticker
GPCR
exchange
NASDAQ
IPO Date
2 February
Total Raised
$161M
Priced at
$15
Current Price
$33.89

snapshot ▲

Struc­ture Ther­a­peu­tics pulled off a $161 mil­lion IPO thanks to a star sci­en­tist co-founder paired with the com­pu­ta­tion­al drug dis­cov­ery com­pa­ny Schrödinger. Struc­ture, known as ShouTi un­til last sum­mer, al­so pulled in $198 mil­lion in pri­vate fund­ing from blue-chip in­vestors and has years of re­search work on G pro­tein-cou­pled re­cep­tors (GPCR) and a port­fo­lio of oral, small-mol­e­cule drugs. Ray­mond Stevens, the co-founder and CEO, is cred­it­ed for map­ping the first hu­man GPCR in 2007 while at Scripps Re­search. The mon­ey raised from the IPO is go­ing to­ward Struc­ture’s small-mol­e­cule, oral drug GS­BR-1290 which “demon­strat­ed glu­cose-de­pen­dent in­sulin se­cre­tion and sup­pressed food in­take, re­sult­ing in weight re­duc­tion,” ac­cord­ing to the S-1 fil­ing. In May, Struc­ture start­ed a Phase IIa study of GS­BR-1290 in adults who are over­weight or obese and in pa­tients with type 2 di­a­betes who are over­weight or obese. Struc­ture is head­quar­tered in San Fran­cis­co and has a site in Shang­hai.

coverage

A service from the Financial Times